DE69805199D1 - Desferri-exochelin zur behandlung von atherosclerose und gefässbeschädigung durch verhinderung der proliferation von glatten muskelzellen - Google Patents

Desferri-exochelin zur behandlung von atherosclerose und gefässbeschädigung durch verhinderung der proliferation von glatten muskelzellen

Info

Publication number
DE69805199D1
DE69805199D1 DE69805199T DE69805199T DE69805199D1 DE 69805199 D1 DE69805199 D1 DE 69805199D1 DE 69805199 T DE69805199 T DE 69805199T DE 69805199 T DE69805199 T DE 69805199T DE 69805199 D1 DE69805199 D1 DE 69805199D1
Authority
DE
Germany
Prior art keywords
desferri
exochelins
treatment
smooth muscle
proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69805199T
Other languages
English (en)
Other versions
DE69805199T2 (de
Inventor
D Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keystone Biomedical Inc
Original Assignee
Keystone Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keystone Biomedical Inc filed Critical Keystone Biomedical Inc
Publication of DE69805199D1 publication Critical patent/DE69805199D1/de
Application granted granted Critical
Publication of DE69805199T2 publication Critical patent/DE69805199T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69805199T 1997-02-06 1998-02-06 Desferri-exochelin zur behandlung von atherosclerose und gefässbeschädigung durch verhinderung der proliferation von glatten muskelzellen Expired - Fee Related DE69805199T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/796,791 US5786326A (en) 1995-02-03 1997-02-06 Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
PCT/US1998/002553 WO1998034619A1 (en) 1997-02-06 1998-02-06 Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation

Publications (2)

Publication Number Publication Date
DE69805199D1 true DE69805199D1 (de) 2002-06-06
DE69805199T2 DE69805199T2 (de) 2002-12-12

Family

ID=25169069

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69805199T Expired - Fee Related DE69805199T2 (de) 1997-02-06 1998-02-06 Desferri-exochelin zur behandlung von atherosclerose und gefässbeschädigung durch verhinderung der proliferation von glatten muskelzellen

Country Status (13)

Country Link
US (1) US5786326A (de)
EP (1) EP1021189B1 (de)
JP (1) JP2001512444A (de)
KR (1) KR20000070462A (de)
CN (1) CN1246796A (de)
AT (1) ATE216888T1 (de)
AU (1) AU719986B2 (de)
CA (1) CA2277022A1 (de)
DE (1) DE69805199T2 (de)
EA (1) EA001870B1 (de)
HU (1) HUP0002012A3 (de)
PL (1) PL335046A1 (de)
WO (1) WO1998034619A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US5952492A (en) * 1998-08-14 1999-09-14 Keystone Biomedical, Inc. Chemical synthesis of exochelins
US6063919A (en) * 1998-08-14 2000-05-16 Keystone Biomedical, Inc. Process for the synthesis of exochelins
AU1258699A (en) * 1998-11-11 2000-05-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
EP1128823A1 (de) * 1998-11-11 2001-09-05 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Verwendung von propionyl-l-carnitine zur herstellung eines apoptose-induzierenden medikaments
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US6783541B2 (en) 2001-11-21 2004-08-31 Miravant Medical Technologies, Inc. Methods for inhibiting or suppressing stenosis of arteriovenous access fistulas and grafts
US7798815B2 (en) * 2002-04-03 2010-09-21 University Of The West Indies Computer-controlled tissue-based simulator for training in cardiac surgical techniques
US7553326B2 (en) 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
EP2413139B1 (de) 2010-07-30 2015-05-20 Universität Leipzig Verfahren und Zusammensetzungen zur Identifizierung von Wirkstoffen mit potentieller Wirkung gegen chronischen Entzündungskrankheiten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
US5721209A (en) * 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury

Also Published As

Publication number Publication date
EP1021189A1 (de) 2000-07-26
EA199900724A1 (ru) 2000-02-28
PL335046A1 (en) 2000-03-27
HUP0002012A2 (hu) 2000-11-28
AU6322898A (en) 1998-08-26
EP1021189B1 (de) 2002-05-02
CN1246796A (zh) 2000-03-08
EA001870B1 (ru) 2001-10-22
CA2277022A1 (en) 1998-08-13
AU719986B2 (en) 2000-05-18
WO1998034619A1 (en) 1998-08-13
JP2001512444A (ja) 2001-08-21
KR20000070462A (ko) 2000-11-25
HUP0002012A3 (en) 2002-09-30
DE69805199T2 (de) 2002-12-12
US5786326A (en) 1998-07-28
ATE216888T1 (de) 2002-05-15

Similar Documents

Publication Publication Date Title
ATE406909T1 (de) Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
ATE555782T1 (de) Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz
DE69805199T2 (de) Desferri-exochelin zur behandlung von atherosclerose und gefässbeschädigung durch verhinderung der proliferation von glatten muskelzellen
DE69637075D1 (de) Zusammensetzungen zur behandlung vaskulärer verletzungen
DE69940444D1 (de) Verabreichung von Resveratrol zur Vorbeugung oder Behandlung von Restenose nach coronaren Eingriffen
IL147727A0 (en) Multi-property nitinol by heat treatment
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
BR9807916A (pt) Conjunto de dispositivo biomédico, método para inibir substancialmente a reestenose em um vaso sanguìneo de um paciente, método para fabricar um conjunto de dispositivo biomédico.
ATE163913T1 (de) Ungesättigte aliphatische dicarbonsäuren
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
SE8803472D0 (sv) Anvaendning av gamma-interferon foer behandling av vaskulaer stenos
CA2162587A1 (en) Therapeutic inhibitor of vascular smooth muscle cells
ES2061853T3 (es) Utilizacion de inhibidores de la eca contra la formacion de neointimas despues de lesion vascular.
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
ATE81467T1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
ES2174144T3 (es) Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.
TR200501763T2 (tr) Tedavi ve ilaç tarama yöntemleri
ATE148626T1 (de) Katecholderivate, deren physiologisch unbedenkliche salze, ester und deren verwendung bei der behandlung von durch lipidperoxidation verursachten gewebeschäden
ATE419037T1 (de) Verwendung eines mittel zur therapie der herzhypertrophie
UA37249C2 (uk) Спосіб інгібування стенозу та/або рестенозу (варіанти), спосіб інгібування рестенозу після проведення операції на коронарній артерії у людини (варіанти), спосіб зниження ймовірності виникнення чи запобігання негострих ішемічних ускладнень при ангіопластиці у людини
BG100367A (en) The use of esters of n-alkylated, 1,4-dihydropyrimidinedicarboxylic acids as medicamentous forms
Wieneke et al. Evaluation of coronary stents in the animal model: a review
Gillespie et al. Stent placement after DVT thrombolysis/mechanical thrombectomy
Lowe et al. READERS’COMMENTS
Hamajima et al. Treatment for Scar Contracture of the Axillary Resion

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee